Virscio announces hiring of Dr. Andrew Puca as Vice President of Business Development

An industry veteran, Dr. Puca will help rapidly expanding translational research organization continue on its growth trajectory

New Haven, Conn., and St. Kitts, West Indies —Virscio, a leading provider of translational research and development services, has announced the appointment of Dr. Andrew Puca as Vice President of Business Development.

A distinguished scientist and business development leader, Dr. Puca earned his Ph.D. in Molecular Cell Biology from the Universita di Siena. Specializing in cancer and stem cell biology, he has made significant contributions to the understanding of the induction of stem cell differentiation via mechanical properties.

Prior to joining Virscio, Dr. Puca gained extensive experience in the pharmaceutical industry, working in pre-clinical and clinical roles at several Contract Research Organizations. Most recently, he was the Director of Corporate and Commercial Development at The Jackson Laboratory, where he was responsible for a team of senior BD focusing on top-tier Pharma strategic accounts. His expertise in market needs, scientific development, and enhancing drug development make him a valuable addition to Virscio.

“We are thrilled to welcome Dr. Puca to our team,” Dr. Matthew Lawrence, Chief Executive Officer of Virscio, said. “His deep expertise in scientific development, coupled with his market acumen and business development experience, make him an invaluable asset to our organization. We look forward to working with him to help drive innovation and deliver meaningful results for our clients.”

Dr. Puca appointment comes at a time of growth and expansion for Virscio. His leadership, expertise in the in the field will help to drive the organization’s continued success in delivering innovative solutions to its clients. In addition to his business acumen, Dr. Puca’s commitment to improving human health through his work and his passion for the ongoing need for good translational models in various therapeutic areas will be of vital importance as the company continues the rapid expansion of its preclinical capabilities in translational models.

Over the last few months, the Connecticut and St. Kitts-based translational research organization has grown its translational research and development services, with the significant expansion of its nonhuman primate capacity and related pharmacokinetics, pharmacodynamics and toxicology capabilities to support growing industry needs. In addition, Virscio has also made sizeable investments in advanced microscopy and image analysis to enhance histopathology service quality and translational value with expanded platform application to non-primate test systems and clinical specimen analysis and interpretation.

“I am thrilled to be joining Virscio and to be part of an organization that is dedicated to advancing research and improving human health,” Puca said. “I look forward to working with the team to further develop Virscio’s capabilities in translational models and to deliver innovative solutions to our clients.”

About Virscio

Virscio is a specialty translational research organization developing and providing innovative preclinical and translational research services, in vivo nonhuman primate disease modeling, and related preclinical and histopathology services to meet the preclinical, translational, and regulatory research needs of the life sciences, biotechnology, and pharmaceutical industries. Virscio specializes in non-GLP and GLP in vivo study design, execution, and sample, data, and image analysis to enable rapid translation of preclinical therapeutic candidates from early proof of concept to IND-enabling studies, leveraging unique and significant access to nonhuman primates and integrated therapeutic domain expertise and capabilities.

For more information, please visit

For media inquiries, please contact:
Christopher Stanley
Chief Business Officer